सत्यमेव जयते

GOVERNMENT OF INDIA
CENTRAL DRUGS STANDARD CONTROL
ORGANISATION (Headquarter)
(Directorate General of Health Services)
Ministry of Health & Family Welfare
FDA Bhavan
ITO, Kotla Road
New Delhi - 110002 (Delhi)
Phone No.: 91-11-23216367
Fax No.: 91-11-23236973
E-Mail : dci@nic.in

File No. CT/25/000031

To,

M/s Pharmaceutical Research Associates India Private Limited,
Level 3 & 4, Prestige Blue Chip Software Park, Municipal No. 9, Hosur Road,
Adugodi, Madiwala Range, Ward No. 63, Bangalore, Tavarekere,
Bangalore South, Bangalore, Karnataka (India) - 560029

Sir,

With reference to your application No. GCT/CT04/FF/2025/47641 dated 28-Mar-2025, please find enclosed herewith the permission in Form CT-06 for conduct of clinical trial titled, **"A Phase 2 Trial of Adagrasib Monotherapy and in Combination with Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination with Pembrolizumab versus Pembrolizumab in Patients with Advanced Non—Small Cell Lung Cancer with KRAS G12C Mutation" Protocol No.: 849-007 version 9.0 dated 24 September 2024 with a total of up-to 51 subjects from India** under the provisions of New Drugs and Clinical Trial Rules, 2019

The permission granted by the Central Licensing Authority to conduct clinical trial shall be subject to following conditions, namely:-

(i) PI Shall be Medical Oncologist only.

(ii) Human biological samples i.e. Whole blood and Tumor tissue or a formalin-fixed paraffin embedded tissue block samples related to clinical trial shall be permitted to be exported for analysis subject to the clearance by port offices of CDSCO. Further, ICMR/DHR permission shall be obtained for export of optional biological samples as per DGFT notification number 72/2023 dated 11.03.2024.

(iii) Clinical trial at each site shall be initiated after approval of the clinical trial protocol and other related documents by the Ethics Committee of that site, registered with the Central Licencing Authority under rule 8;

(iv) where a clinical trial site does not have its own Ethics Committee, clinical trial at that site may be initiated after obtaining approval of the protocol from the Ethics Committee of another trial site; or an independent Ethics Committee for clinical trial constituted in accordance with the provisions of rule 7:

Provided that the approving Ethics Committee for clinical trial shall in such case be responsible for the study at the trial site or the centre, as the case may be:

Provided further that the approving Ethics Committee and the clinical trial site or the bioavailability and bioequivalence centre, as the case may be, shall be located within the same city or within a radius of 50 kms of the clinical trial site;

(v) in case an ethics committee of a clinical trial site rejects the approval of the protocol, the

details of the same shall be submitted to the Central Licensing Authority prior to seeking approval of another Ethics Committee for the protocol for conduct of the clinical trial at the same site

(vi) the Central Licencing Authority shall be informed about the approval granted by the Ethics Committee within a period of fifteen working days of the grant of such approval;

(vii) clinical trial shall be registered with the Clinical Trial Registry of India maintained by the Indian Council of Medical Research before enrolling the first subject for the trial;

(viii) clinical trial shall be conducted in accordance with the approved clinical trial protocol and other related documents and as per requirements of Good Clinical Practices Guidelines and the provisions of these rules;

(ix) status of enrolment of the trial subjects shall be submitted to the Central Licencing Authority on quarterly basis or as appropriate as per the duration of treatment in accordance with the approved clinical trial protocol, whichever is earlier;

(x) six monthly status report of each clinical trial, as to whether it is ongoing, completed or terminated, shall be submitted to the Central Licencing Authority electronically in the SUGAM portal;

(xi) in case of termination of any clinical trial the detailed reasons for such termination shall be communicated to the Central Licencing Authority within thirty working days of such termination;

(xii) any report of serious adverse event occurring during clinical trial to a subject of clinical trial, shall, after due analysis, be forwarded to the Central Licencing Authority, the chairperson of the Ethics Committee and the institute where the trial has been conducted within fourteen days of its occurrence as per Table 5 of the Third Schedule and in compliance with the procedures as specified in Chapter VI;

(xiii) in case of injury during clinical trial to the subject of such trial, complete medical management and compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty working days of the receipt of order issued by Central Licencing Authority in accordance with the provisions of the said Chapter;

(xiv) in case of clinical trial related death or permanent disability of any subject of such trial during the trial, compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty working days of receipt of the order issued by the Central Licencing Authority in accordance with the provisions of the said Chapter;

(xv) the premises of the sponsor including his representatives and clinical trial sites, shall be open for inspection by officers of the Central Licencing Authority who may be accompanied by officers of the State Licencing Authority or outside experts as authorised by the Central Licencing Authority, to verify compliance of the requirements of these rules and Good Clinical Practices Guidelines, to inspect, search and seize any record, result, document, investigational product, related to clinical trial and furnish reply to query raised by the said officer in relation to clinical trial;

(xvi) where the new drug or investigational new drug is found to be useful in clinical development, the sponsor shall submit an application to the Central Licencing Authority for permission to import or manufacture for sale or for distribution of new drug in India, in accordance with Chapter X of these rules, unless otherwise justified;

(xvii) the laboratory owned by any person or a company or any other legal entity and utilised by that person to whom permission for clinical trial has been granted used for research and development, shall be deemed to be registered with the Central Licensing Authority and may be used for test or analysis of any drug for and on behalf of Central Licensing Authority;

(xviii) the Central Licencing Authority may, if considered necessary, impose any other condition in writing with justification, in respect of specific clinical trials, regarding the objective, design, subject population, subject eligibility, assessment, conduct and treatment of such specific clinical trial;

(xix) the sponsor and the investigator shall maintain the data integrity of the data generated during clinical trial.

(xx) Merely granting permission to conduct the **clinical trial** with the Investigational Drug Product does not convey or imply that, based on the **clinical trial study data** generated

with the investigational drug, permission to market this drug in the country will automatically be granted to you;

(xxi) The permission to initiate clinical trial granted under rule 22 in form CT-06 or automatic approval under rule 23 in Form CT 4A shall remain valid for a period of **two years** from the date of its issue, unless extended by the Central Licencing Authority.

Yours faithfully,

RAJEEV SINGH RAGHUVANSHI
Digitally signed by RAJEEV SINGH RAGHUVANSHI
Date: 2025.10.22 17:46:36 +05'30'

(Dr. Rajeev Singh Raghuvanshi)
Drugs Controller General (India) &
Central Licencing Authority
Stamp

FORM CT-06

(See rules 22,25,26,29 and 30)

PERMISSION TO CONDUCT CLINICAL TRIAL OF NEW DRUG OR INVESTIGATIONAL NEW DRUG

1. The Central Licensing Authority hereby permits **M/s Pharmaceutical Research Associates India Private Limited, Level 3 & 4, Prestige Blue Chip Software Park, Municipal No. 9, Hosur Road, Adugodi, Madiwala Range, Ward No. 63, Bangalore, Tavarekere, Bangalore South, Bangalore, Karnataka (India) - 560029** to conduct clinical trial of the new drug or investigational new drug as per **Protocol No.: 849-007 version 9.0 dated 24 September 2024** in the below mentioned clinical trial sites [As per Annexure].-

2. Details of new drug or investigational new drug and clinical trial site [As per Annexure].

3. This permission is subject to the conditions prescribed in part A of Chapter V of the New Drugs and Clinical Trials Rules, 2019 under the Drugs and Cosmetics Act, 1940.

Place: New Delhi
Date _____

RAJEEV SINGH RAGHUVANSHI
Digitally signed by RAJEEV SINGH RAGHUVANSHI
Date: 2025.10.22 17:46:48 +05'30'

(Dr. Rajeev Singh Raghuvanshi)
Drugs Controller General (India) &
Central Licencing Authority
Stamp

Note: The permission to initiate clinical trial granted under rule 22 in form CT-06 shall remain valid for a period of **two years** from the date of its issue, unless extended by the Central Licencing Authority.

Annexure:
Details of new drug or investigational new drug:

Names of the new drug or investigational new drug	Adagrasib
Therapeutic class:	KRAS inhibitor
Dosage form:	Tablets
Composition:	Adagrasib (MRTX849)=200.0000 milligram (mg) In House Specification Active
Indications:	For the treatment of patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC)

Annexure:

Details of clinical trial site:

Sr. No.	Names and address of clinical trial site	Ethics committee details	Name of investigator
1.	State Cancer Institute, Indira Gandhi Institute of Medical Sciences, Sheikhpura, Patna Sheikhpura Bihar - 800014	Institutional Ethics Committee, IGIMS, Sheikhpura, Indira Gandhi Institute of Medical Sciences Sheikhpura Raja Bazar, Patna, Bihar- 800014, India ECR/640/Inst/BR/2014/RR-20	Dr. Alok Ranjan
2.	Mysore Medical College and Research Institute, K.R. Hospital, Department Of Radiation Oncology, Mysore Medical College and Research Institute, K.R. Hospital, Irwin Road Mysore Karnataka -570001	IEC-MMC and RI and Associated Hospital Mysore Medical College and Research Institute, Irwin Road, Mysore, Karnataka- 570001, India ECR/134/Inst/KA/2013/RR-19 (Expired On 26/Nov/2024 and applied for Renewal) EC/RENEW/INST/2024/6487	Dr. Vikas L
3.	Nirmal Hospital Pvt. Ltd., Ring Road, Surat Surat Gujarat -395002	Nirmal Hospital Ethics Committee Nirmal Hospital Pvt. Ltd., Ring Road, Surat-395002, Gujarat, India ECR/390/Inst/GJ/2013/RR-24	Dr Anshul Rajendra Prasad Agarwal

4.	Basavatarakam Indo American Cancer Hospital and Research Institute, Road No 10, Banjarahills Hyderabad Telangana -500034	Institutional Ethics Committee, Basavatarakam Indo American Cancer Hospital & Research Institute, Road No 10, Banjara Hills, Hyderabad- 500034, Telangana, India ECR/7/Inst/AP/2013/RR-20	Dr Senthil J Rajappa
5.	Marathwada Cancer Hospital and Research Institute, Department of Oncology, Marathwada Cancer Hospitaland Research Institute Plot No. 2, Dnyaneshwar Nagar, Infront of Stadium, Garkheda Maharashtra - 431002	MGM Ethics Committee for Research on Human Subjects, MGM Campus, MGM Medical College and Hospital, N-6 CIDCO, Aurangabad, Maharashtra, India – 431003 ECR/581/Inst/MH/2014/RR-20	Dr. Mule Tushar Rajendra
6.	Amrita Institute of Medical Sciences, AIMS Ponekkara P.O. Kochi Kochi Kerala	Institutional Ethics Committee, Amrita Institute of Medical Sciences, AIMS Ponekkara P.O., Edappally, Ernakulam Kochi – 682041, Kerala, India ECR/129/Inst/KL/2013/RR-24	Dr K Pavithran
7.	Indraprastha Apollo Hospitals, Sarita Vihar, Delhi Mathura Road, New Delhi New Delhi Delhi - 110076	Institutional Ethics Committee – Clinical Studies, Indraprastha Apollo Hospitals, Delhi – Mathura Road, Sarita Vihar, New Delhi – 110076 India ECR/5/Inst/DL/2013/RR-19 Applied for renewal EC/RENEW/INST/2024/17961	Dr Pratap Kishore Das
8.	Marengo CIMS Hospital Pvt. Ltd., Plot No 67-1, opp. Panchamrut Bunglows, Nr.Shukan Mall, off. Science City Road, Sola Sola Gujarat - 380060	Ethics Committee of Care Institute of Medical Sciences, Marengo CIMS Hospital Pvt. Ltd. Plot 67/1, Nr. Shukan Mall, opp. Panchamrut Bunglows, off. science city road, Sola, Ahmedabad-380060, Gujarat, India. ECR/206/Inst/GJ/2013/RR-24	Dr Bhavesh B Parekh
9.	R.K. Birla Cancer Center, S.M.S. Medical College and Attached Hospital, JLN Marg Jaipur Rajasthan - 302004	Ethics committee, S.M.S. Medical College & Attached Hospitals Office of Ethics Committee, Second Floor, New Academic Block, S.M.S. Medical College & Attached Hospitals, J.L.N. Marg, Jaipur-	Dr Sandeep Kumar Jasuja

		302004, Rajasthan, India ECR/26/Inst/RJ/2013/RR-24	
10.	Netaji Subhas Chandra Bose Cancer Hospital, 3081Nayabad, New Garia, Kolkata West Bengal - 700094	Ethics Committee N.S.C.B.C Research Institute, Netaji Subhas Chandra Bose Cancer Hospital 3081 Nayabad, New Garia, Kolkata, West Bengal, India – 700094 ECR/286/Inst/WB/2013/RR-24	Dr Rajiv Lochan Jena
11.	Meenakshi Mission Hospital and Research Centre, Department of Oncology, LakeArea, Melur Road. Madurai Tamil Nadu - 625107	Institutional Ethics Committee Meenakshi Mission Hospital and Research Centre Room no: 6701, 6th Floor, Meenakshi Mission Hospital & Research Centre, Lake area, Melur Road, Madurai- 625107, Tamil Nadu, India ECR/398/Inst/TN/2013/RR-24	Dr Saju Sekharan Vilasini
12.	Hemato Oncology Clinic Ahmedabad Pvt. Ltd., Nirmaya Complex Ground Floor to Third Floor, Beside Pandit Dindayal Upadhyay Auditorium, Rajpath Club Road, Off S G Highway Ahmedabad Gujarat - 380054	Swarnim Ethics Committee, Netralaya Super Speciality Eye Hospital, 1st Floor, KayDee House, Opp. Gujarat Gas, Parimal Garden Cross Road, Ellisbridge, Ahmedabad – 380006, Gujarat, India ECR/1922/Inst/GJ/2024	Dr Chirag Jyotiker Desai
13.	KLES Dr Prabhakar Kore Hospital and Medical Research Centre, Nehrunagar Belagavi Karnataka - 590010	Institutional Ethics Committee, KLE Academy of Higher Education & Research, JNMC Campus, Nehru Nagar, Belgavi- 590010, Karnataka India ECR/211/Inst/KA/2013/RR-24	Dr Rohan Bhise
14.	Narayana Superspeciality Hospital, Department: Medical Oncology, ground floor, room no-18, 120/1, Andul Road, Howrah-711103, West Bengal, India	NSH Ethics Committee, Narayana Superspeciality Hospital, 8th Floor, 120/1, Andul Road, Howrah-711103, West Bengal, India ECR/1006/Inst/WB/2018/RR-21	Dr. Chandrakanth MV
15.	Mahamana Pandit Madan Mohan Malaviya Cancer Centre, Sundar Bagiya, Near Nariya Gate, Banaras Hindu University	Institutional Ethics Committee, MPMMCC & HBCH, Mahamana Pandit Madan Mohan Malaviya Cancer Centre, Sundar Bagiya, Near	Dr Anuj Gupta

	Campus Varanasi Uttar Pradesh - 221005	Nariya Gate, Banaras Hindu University Campus, Varanasi, Uttar Pradesh, 221005, India ECR/1501/Inst/UP/2021	
16.	Tata Memorial Centre, Tata Memorial Hospital, Dr. Ernest Borges Road, Parel Mumbai Maharashtra - 400012	Institutional Ethics Committee-I, Tata Memorial Hospital, 3rd Floor, Main Building, Dr. Ernest Borges Road, Parel (E), Mumbai- 400012, Maharashtra, India Institutional Ethics Committee-II, Tata Memorial Hospital, 3rd Floor, Main Building, Dr. Ernest Borges Road, Parel (E), Mumbai 400012, Maharashtra, India EC-I: ECR/170/Inst/MH/2013/RR-22 IEC-II: ECR/414/Inst/MH/2013/RR-24	Dr Kumar Prabhash

****